Aquestive Therapeutics
AQST
40 hedge funds and large institutions have $61M invested in Aquestive Therapeutics in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 17 closing their positions.
0.39% more ownership
Funds ownership: 57.72% → 58.11% (+0.39%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 49 → 40 (-9)
39% less capital invested
Capital invested by funds: $99.6M → $61M (-$38.7M)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
67% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.02M |
| 2 |
Millennium Management
New York
|
+$1.36M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$440K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$362K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$304K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$2.19M |
| 2 |
BlackRock
New York
|
-$2.15M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$417K |
| 4 |
State Street
Boston,
Massachusetts
|
-$338K |
| 5 |
Goldman Sachs
New York
|
-$278K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
51
American International Group
New York
| – | -$50K | -7,211 | Closed |
|
52
Victory Capital Management
San Antonio,
Texas
| – | -$35K | -5,000 | Closed |
|
53
New York State Common Retirement Fund
Albany,
New York
| – | -$31K | -4,500 | Closed |
|
|
SO
54
STRS Ohio
Columbus,
Ohio
| – | -$10K | -1,500 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | -$7K | -951 | Closed |
|
|
AIP
56
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$3K | -400 | Closed |
|
|
LTFS
57
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$512 | +100 | New |
|
AQST Hedge Fund Activity: Q2 2019 in Review
40 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2019, worth a combined $61M — down 39% from $99.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of AQST and 9 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 5 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $3.02M. The largest seller was AllianceBernstein, exiting entirely with an estimated $2.19M sold.
- 40 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2019, down from 49 in Q1 2019.
- Funds reported $61M of Aquestive Therapeutics stock for Q2 2019, down 39% quarter-over-quarter.
- 9 funds opened new Aquestive Therapeutics positions in Q2 2019 and 17 closed out, a net change of -8 holders.
- The largest Aquestive Therapeutics buyer in Q2 2019 was Opaleye Management, an estimated $3.02M added.
- The largest Aquestive Therapeutics seller in Q2 2019 was AllianceBernstein, an estimated $2.19M sold.
Based on aggregated 13F filings for Q2 2019.